teclistamab
janssen,genmab
day 3 #ims2022 oral abstract session nct04557098: phase 2- teclistamab, in participants with relapsed or refractory myeloma (majestec-1) #mmsm #multiplemyeloma #curemyeloma 
Multiple Myeloma Education Platform for Myeloma Community